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Abstract 
Background: Triple negative breast cancer (TNBC) in humans is defined by the absence of oestrogen 
receptor (ER), progesterone receptor (PR) and HER2 overexpression. Mammalian target of rapamycin 
(mTOR) is overexpressed in TNBC and it represents a potential target for the treatment of this aggressive 
tumour. Feline mammary carcinoma (FMC) is considered to be a model for hormone-independent human 
breast cancer. This study investigated mTOR and p-mTOR expression in FMC in relation to triple negative 
(TN) phenotype. 
Results: The expression of mTOR, p-mTOR, ERct, PR and HER2 was evaluated in 58 FMCs by 
immunohistochemistry and in six FMC cell lines by Western blot analysis. 53.5% of FMC analyzed were ER, 
PR, HER2 negative (TN-FMC) while 56.9% and 55.2% of cases expressed mTOR and p-mTOR respectively. 
In this study we found that m-TOR and p-mTOR were more frequently detected in TN-FMC and in HER2 
negative samples. 
Conclusions: In this study, we demonstrate that there is also a FMC subset defined as TN FMC, which is 
characterised by a statistically significant association with m-TOR and p-mTOR expression as 
demonstrated in human breast cancer. 
Background  
Triple negative breast cancer (TNBC) in humans is a distinct subset of breast cancer that is defined by the 
lack of immunohistochemical (IHC) expression of the oestrogen receptor (ER) and progesterone receptor (PR) 
and a lack of human epidermal growth factor receptor 2 (HER2) overexpression [1]. This subtype of cancer 
comprises 15-20% of patients with breast cancer for which targeted therapy is currently unavailable [2,3]. To 
develop new targeted therapies for this subset of tumours, researchers focused their attention on the different 
intracellular cell signaling pathways responsible for tumour growth, invasion and metastasis in TNBC [4]. One 
of the most pathways studied is the PI3K/AKT/mTOR pathway, which can be activated by different membrane 
tyrosine kinase receptors, including the epidermal growth factor 
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 (EGFR) family of growth receptors, insulin-like growth factor receptor (IGF-R) and ERa [5]. 
A key downstream component of the PI3K pathway is the mammalian target of rapamycin (mTOR), a 
serine/ threonine kinase involved in tumour formation and progression [3]. mTOR is activated by 
phosphorylation at Ser2448 via the PI3K kinase/AKT signalling pathway and is autophosphorylated at 
Ser2481 [6]. mTOR has two main downstream messengers, the ribosomal p70 S6 kinase (S6K1) and the 
eukaryotic translation initiation factor 4E-binding protein (4E-BP1) [7]. The activation of S6K1 and 4E-BP1 
by mTOR induces mRNA translation and a subsequent increase in protein synthesis that is essential for cell 
growth and proliferation [8,9]. 
Based on its role in tumour formation and progression, targeted therapy against mTOR has been shown to 
decrease tumour growth in model systems [10,11] and several mTOR inhibitors, such as everolimus, 
deforolimus and temsirolimus, have been used in clinical trials For the treatment of multiple cancer types 
including breast cancer [12]. 
Recently, it has been reported that the activated form of mTOR, phospho-mTOR (p-mTOR), detected at 
nuclear level, was expressed more frequently in triple negative (TN) human breast cancers compared with 
non-TN cancers [3], suggesting that mTOR may play a more important role in the progression of TNBC and 
could be considered a new target for the treatment of this tumour sub-type [9,13-15]. 
Feline mammary carcinoma (FMC) shares many biological and molecular similarities with human breast 
cancer [16] and is considered an excellent model for aggressive, hormone-independent human breast 
cancers overexpressing HER2 [17-19]. The percentage of FMCs that are negative for ER and PR range from 
37% [20] to 54.2% [21]. Regarding HER2 expression in feline mammary carcinomas scientific data are 
controversial. Some authors [19,22,23] showed that HER2 is expressed from 39% to 56.3% which is similar 
to human breast cancer (20-30%) [24] while Rasotto and colleagues [25] showed HER2 expression in only the 
5% of analyzed cases. We have recently found that AKT is expressed in FMCs, and its expression 
correlated with poor prognosis [22], suggesting a role for the PI3K/AKT/mTOR pathway in FMC 
pathogenesis. 
The aim of this study was to investigate the role of mTOR and p-mTOR in feline mammary tumours and 
cell lines with regard to the TN FMC status and clinical outcome to understand the role of mTOR in feline 
mammary tumour progression and to evaluate whether the feline model may be considered the first animal 
model for the TNBC. 
Methods 
Tissue samples and histology 
Tissue samples from 58 cases of FMC, 18 benign lesions and 8 normal mammary tissues were collected from 
the 2000-2008 archives of the Diagnostic Laboratories of the Department of Veterinary Sciences of the 
University of Turin, Italy, and the Department of Animal Pathology, University of Cordoba, Spain. Details of 
age, breed, ovariectomy status and tumour size data were retrieved from the hospital database. Postoperative 
clinical, radiological and echographic examinations at 6, 12, 18 and 24 months after surgery were performed 
by veterinarians to detect the presence of distant organ metastases or the local recurrence of the primary 
tumour. Animals that died due to mammary carcinoma were submitted for post-mortem examination to 
confirm the pathological diagnosis; subjects that died of non-tumour-related causes (confirmed by 
necroscopy) during the follow-up period were excluded from the study. The disease-free interval (DFI) was 
considered to be the number of days between surgery and 
tumour recurrence and/or evidence of metastatic disease while the overall survival (OS) was considered the 
period between surgery and animal death. Normal mammary tissue used as control were collected from 
necroscopy (after owners' consensus) of female cats that were neither spayed nor treated with hormonal therapy 
during their life and died spontaneously at the Veterinary Hospital of the University of Turin. 
The samples were fixed in 4% neutral buffered formalin, paraffin embedded, sectioned at 4 µm and stained 
with haematoxylin and eosin. Tumours were examined histologically and classified according to the World 
Health Organization (WHO) classification for tumours of domestic animals [26]. Carcinomas were classified by 
differentiation status [27] and surgical margins were evaluated to confirm that all masses were completely 
surgically ablated. 
Immunohistochemistry 
IHC analysis was performed on 4 micron paraffin sections from all mammary tissue samples collected. 
Endogenous peroxidase activity was blocked with 3% hydrogen peroxide in methanol for 20 min at room 
temperature. The sections were subjected to high-temperature antigen unmasking by incubation with 98°C 
citric acid buffer (pH 6.0). Primary anti-human antibodies were used against mTOR (rabbit polyclonal 
antibody; catalogue number 2983, Cell Signaling Technology; diluted 1:50, overnight incubation), 
phospho-mTORSer2448-49F9 (rabbit polyclonal antibody; catalogue number 2976, Cell Signaling 
Technology; diluted 1:50, overnight incubation), c-erbB-2 oncoprotein (rabbit polyclonal antibody, Dako; 1:200 
dilution; 1 h of incubation), PR (mouse monoclonal antibody, clone PR10A9 IgG2A, Immunotech 
Laboratories; 1:750 dilution, overnight incubation) and ERa (rabbit polyclonal, Zymed Invitrogen; 1:80 
dilution; 1 h of incubation). Antibodies were detected with avidin-biotin peroxidase complex techniques using 
the Vectastain Elite ABC kit (Vector Laboratories). External positive controls were paraffin-embedded sections 
of MCF7 cells for mTOR and p-mTOR [28], a human breast carcinoma positive for HER2 and feline normal 
uterus for ERa and PR. Specificity of primary antibody was carried out incubating primary antibody with 
excess of specific peptide used to immunize rabbits (available from Cell Signaling Technology). After 
incubation the protein labeling was abrogated by the previous incubation of antibodies with the peptide. 
The immunolabelled slides were randomised and masked for blinded examination, which was performed 
independently by three observers (LM, SI and YM); when there was disagreement (<5% of the slides), a consensus 
was obtained using a multi-head microscope. Slides with >20% tumour immunolabelled cells were considered to 
be positive for mTOR and phospho-mTOR [3]. HER2 immunoreactivity 
was scored according to the HerceptTest method (Dako), which is commonly used in human pathology and also 
adopted for FMCs [29]. ERa and PR positivity was evaluated as described previously [22]. 
Cell lines and Western blot analysis 
Six feline mammary tumour cell lines were evaluated: FYCp, P248m, FMCp, FMCm, FKNp and FNNm; 
the last four cell lines were kindly provided by Professor Sasaki, Japan [30]. P248m cell lines derived from a 
pulmonary metastasis of primary tubulopapillary mammary carcinomas [31] while FYC cell lines derived 
from tubulopapillary FMC [19,32,33]. Regarding cell lines kindly provided by Dr. Sasaki please see the 
reference [34]. The letters 'p' and 'm' indicate cell lines derived from primary and metastatic lesions, respectively. 
FYCp, FMCp, FMCm, FKNp and FNNm cells were grown in Roswell Park Memorial Institute (RPMI) 
medium, whereas P248m was grown in Dulbecco's modified Eagle's medium (DMEM). In all cases, the 
medium was supplemented with 10% fetal calf serum, 100 ng/ml penicillin, 100 µg/ml streptomycin and 1.5 
mg/ml amphotericin B. For P248 cells, 10 µg/ml insulin was added to the DMEM. 
Total protein were extracted at 80% of cellular confluence in boiling lysis buffer containing 1% sodium 
dodecyl sulphate (SDS) and 0.1 M Tris HC1 (pH 6.8). Total proteins from each sample (40 µg) were separated 
on an 8% SDS-polyacrylamide (PAGE) gel and transferred onto a Hybond-C Extra membrane (Amersham 
Biosciences). Membranes were blocked at room temperature for 2 h with Tris-buffered saline (TBS, 10 mM 
Tris, 150 mM NaCl, pH 7.4) containing 10% bovine serum albumin, then incubated overnight at 4°C with the 
appropriate primary antibodies, including anti-ER, PR, HER2, mTOR (see antibodies used in IHC), 
phospho-mTORSer2448 (rabbit polyclonal antibody; catalogue number 2971; Cell Signaling 
Technology) or α-tubulin (mouse monoclonal antibody; catalogue number 3873; Cell Signaling 
Technology). After incubating with a horseradish peroxidase-linked secondary antibody that was diluted 
1:2000 in TBS-Tween, the membranes were washed in TBS-Tween for 30 min and incubated with an 
enhanced chemiluminescence reagent (Super Signal West Pico Mouse IgG Detection Kit, Thermo 
Scientific). The proteins were visualised by exposing the membrane to a Hyperfilm ECL autoradiography 
film. Every experiment was carried out in triplicate and bands intensity was analyzed by using Biorad 
ChemiDoc XRS and ChemiDoc MP imaging system software. 
Statistical analysis 
The IHC results were grouped into contingency tables and analysed using Fisher's exact or/2 tests. The DFI 
and OS  analyses were performed using the  Kaplan Meier 
method with a log rank test. P <0.05 was considered to be statistically significant. The data were analysed usin
g GraphPad Prism Software v. 4.0. 
 
 
 
 
Results 
Clinicopathologic characteristics 
The mean age of cats at the time of diagnosis was 11.32 ± 2.69 years (range 6-18 years). Of the 58 animals, 11/58 
(19.0%) were spayed and 4/58 (6.9%) were cyclically treated with progesterone. At the time of diagnosis, 
histologically confirmed lymph node metastases were present in 5/58 (8.6%) FMC cases and no clinically and 
radio-graphically observable distant organ metastases were present. Of the 58 animals diagnosed with 
FMC, 13 (22.4%) did not present tumour recurrence and 45 (77.6%) relapsed 2-23 months after surgery. The 
mean DFI was 196.4 ± 153.1 days. Information regarding the OS was available for 25 cases within a 24 months 
follow-up period. Eighteen patients presented distant organ metastases during the follow up period and died of 
cancer-related causes confirmed at post-mortem examination. 
The mean gross size of the tumours was 2.3 ± 1.8 cm and 15/58 (25.9%) tumours were <1.0 cm in 
diameter. All tumours were surgically completely ablated, which was confirmed histopathologically. A 
total of 39/58 (67.2%) tumours were tubulopapillary carcinoma, 11/58 (19.0%) were solid carcinoma, 7/58 
(12.1%) were cribriform carcinomas and 1/58 (1.7%) was mucinous carcinoma. According to histological 
classification, 9/58 (15.5%) tumours were grade I, 24/58 (41.4%) were grade II and 25/58 (43.1%) were 
grade III. Out of the 18 benign mammary lesions used as controls, eight were lobular hyperplasia, five 
were fibroadenomas and five were simple adenomas. 
 
Figure 1 DFI in patients with TN and 
no-TN feline mammary carcinomas. 
Kaplan-Meier estimates for disease free interva 
probability in TN-FMCs (TN) and no 
  
Figure 2 mTOR expression in tubulopapillary carcinoma, a. Mammary gland. I grade tubulopapillary carcinoma. Neoplastic cells are 
characterised by diffuse and moderate cytoplasmic immunopositivity for mTOR. Streptavidin-biotin-peroxidase method. Mayer's haematoxylin 
counterstaining. Scale bar = 50 µM b. Mammary gland. I l l  grade tubulopapillary carcinoma. Neoplastic cells are characterised by diffuse and 
moderate cytoplasmic immunopositivity for mTOR. Streptavidin-biotin-peroxidase method. Mayer's haematoxylin counterstaining. Scale bar = 50 
µM. 
Immunohistochemistry 
Immunoreactive products to ER monoclonal antibody in feline uterus used as positive control were 
observed in the nuclei of epithelial and stromal cells of the endometrium and the nuclei of smooth muscle 
myometrial cells. Immunoreactive products to PR monoclonal antibody in feline uterus used as control were 
observed in the nuclei of stromal cells and in the surface and glandular epithelial cells of the endometrium 
and of smooth muscle cells of the myometrium. In the normal mammary glands and in the mammary tumors 
object of this study immunoreactive products to ER and PR were observed in the nuclei of acinar and ductal 
glandular epithelial cells. 
The human mammary carcinoma used as control for HER2 demonstrated a strong complete membrane 
staining in all the tumoral cells (HerceptTest 3+) while in feline mammary carcinomas, immunoreactive products 
were seen in the membrane and the cytoplasm of neoplastic cells and, according to HerceptTest method, only 
complete membrane staining was considered positive. 
Based on the lack of the IHC expression of ER and the PR, as well as the lack of HER2 overexpression, 31/58 
(53.4%) cases were TN-FMC and 27/58 (46.6%) were non-TN-FMC. Considering the immunophenotype of 
the steroid receptors, we found that 46/58 (79.31%) were ER-/PR-, 3/58(5.17%) were ER+/PR-, 6/58 (10.34%) 
were ER-/PR + and 3 were ER+/PR+. None of the feline benign mammary lesions, including the normal 
mammary tissue analysed, were of triple negative subtype. TN-FMCs compared to not TN-FMCs did not 
presented statistically significative differences in terms of clinicopathological features. The mean DFI 
observed in patients with TN lesions was shorter than the DFI reported in patients with non-TN cancer (150 
days vs. 250) but not statistically significant (P >0.05) such as OS (Figure 1). 
Immunoreactive products in paraffine-embedded sections of MCF7 cells, used as control for mTOR and 
p-mTOR, were seen in the 100% of the stained cells in 
the cytoplasm and in both the cytoplasm and nuclei respectively. Positive mTOR expression was detected in the 
cytoplasm of neoplastic cells by IHC analysis (Figures 2a and 2b) and was uniformly distributed within the 
tumour mass. Expression of p-mTOR was detected more frequently in the nucleus (Figure 3) and was also 
located in the cytoplasm. According to Walsh and colleagues [3], only the nuclear and peri-nuclear location 
was considered to be positive. When not diffusely located within tumour cells, p-mTOR was present in luminal 
epithelial cells. A statistically significant positive association was found between mTOR and p-mTOR 
expression (P <0.05). In benign lesions, three cases showed cytoplasmic positiv-ity for mTOR (two 
fibroadenoma and one adenoma), while none of the benign lesions were p-mTOR positive. The normal 
feline mammary tissues were mTOR and p-mTOR negative. 
  
 
  
Figure 3 - phospho-mTOR expression in tubulopapillary carcinoma. Mammary gland. Ill  grade 
tubulopapillary carcinoma. About 60% of neoplastic cells are characterised by strong nuclear 
immunopositivity for p-mTOR. Streptavidin-biotin-peroxidase method. Mayer's haematoxylin 
counterstaining. Scale bar= 100 µ^l 
Table 1 summarises the relationship between mTOR, p-mTOR, tumour characteristics and TN status. 
mTOR and p-mTOR were more frequently detected in TN compared with non-TN samples (P <0.05 for mTOR; 
P <0.001 for p-mTOR). There were no significant differences between the DFIs and OS analysis in relation to 
mTOR and p-mTOR expression. We also evaluated if the high expression of m-TOR and p-mTOR found in 
our samples was correlated to HER2, PR and ER expression expression. We found that samples HER2 
negatives are statistically correlated to samples p-mTOR (P < 0.001) and m-TOR (P <0.05) positives (Table 1) 
while no correlations 
were found comparing mTOR and p-mTOR expression in relation to ER and PR phenotype. 
Western blot analysis 
To validate the antibodies used in immunohistochemistry and to further investigate mTOR expression in 
TN-FMC, Western blot analysis of mTOR, p-mTOR, ER, PR and HER2 was performed on FMC cell lines 
(Figure 4). A specific 289 kDa band corresponding to human mTOR was found in all cell lines analysed. A 
specific 286 kDa band corresponding to phospho-mTORSer2448-49F9 was visible in all cell lines, with the 
strongest expression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 Relationships between tumour characteristics and expression of mTOR and p-mTOR 
 
 Figure 4 Western blot. a. Western blot analysis of HER2, oestrogen receptor a (ERa), progesterone 
receptor (PR), mTOR and p-mTOR expression in FYCp (lane 1), P248m (lane 2), FMCp (lane 3), FMCm 
(lane 4), FKNp (lane 5) and FNNm (lane 6) cell lines, a Tubulin expression was used as the loading control, 
b. Measure of band intensity normalized to a tubulin. Error bars demonstrate standard deviation. 
in FMCm and FNNm. A band corresponding to ERa (67 kDa) was also present in the FYC cell line, while 
specific 116 kDa (B form) and 81 kDa (A form) double bands corresponding to PR were present in the 
FNNm cell line. HER2 band (185 kDa) was detected in all of the FMC cell lines. The FKNp, FMCm, 
P248m and FYCp cell lines demonstrated higher expression of HER2 than the FYCp, FMCp and FNNm cell 
lines; cell line derived from the metastatic tumor (FMCm) shows a higher expression of HER2 compared to 
the cell line derived from the primary tumor (FMCp). 
Discussion 
This study provides the first evidence that felines also have a subset of mammary carcinoma that is defined 
by the lack of immunohistochemical ER and PR expression and a lack of HER2 overexpression, which we 
identify as TN FMC. Similar to human breast cancer, these tumours demonstrate high expression of 
mammalian target of ra-pamycin (mTOR). Human TNBCs have a poor prognosis, because such cancers have no 
effective therapeutic targets, e.g. ER for endocrine therapy or human epidermal growth factor receptor 2 
receptors for anti-HER2 therapy [35-37]. For these reasons, several efforts are underway to better characterize 
this type of tumour to develop new targeted therapies and to identify a new animal model for comparative 
oncology. 
Among spontaneous tumours occurring in domestic animals, feline mammary tumour is widely considered 
an excellent model for human breast cancer. In particular, the 
high percentage of FMCs negative for ER and PR, ranging from 37% [20] to 54.2% [21], makes this tumour a 
suitable model of breast cancer hormone independent subtype [24]. Moreover we and others [19,22,23] 
showed that HER2 is expressed from 39% to 56.3% and is a negative prognostic factor [23] similar to human 
breast cancer (20-30%) [24] while Rasotto and colleagues [25] demonstrated that only the 5.5% of FMCs was 
HER2 positive and it is not a prognostic factor in FMCs. This discrepancy might be due to the use of different 
antibodies, criteria of evaluation and other issues related to discordant study protocols [38] and, considering 
the potential importance of FMCs as model for human breast cancer, a standardised method for the detection of 
HER2 expression and cellular localisation in feline mammary tumours is urgently needed. In addition, our 
group has demonstrated that p-AKT is expressed in a high percentage of FMCs and correlated to poor 
prognosis [22], suggesting that the PI3K/AKT/mTOR pathway is activated and associated with oncogenesis 
in the feline species, which is similar to that in humans [14] and recently also demonstrated in canine tumour 
cells [39] These assumptions prompted us to better understand the involvement of mTOR in FMC. 
The IHC results obtained in this study demonstrated that there is a FMC tumour subtype that we can 
characterise as TN FMC since 53.4% of feline FMCs do not express ER and PR and also lack HER2 
overexpression. These data are consistent with the description of human TNBCs [1] even if more expressed 
and confirm the presence of a new entity in feline mammary oncology. 
As previously described, one of the promising human TNBC therapies is the inhibition of the 
PI3K/AKT/mTOR pathways, particularly mTOR, which is more frequently expressed in TN cancer compared 
with its non-TN counterparts [3] and is considered to be a potential anticancer therapy molecular target 
[9,13-15]. We have previously shown that the PI3K/AKT/PTEN pathway was activated in feline mammary 
carcinoma and correlated with poor prognosis [22], while there are no scientific data demonstrating mTOR 
expression in FMC tissues and cell lines with respect to the TN phenotype and AKT activation as 
demonstrated in humans. To elucidate whether feline mTOR was also phosphorylated by AKT, we 
evaluated both mTOR and p-mTOR at serine 2448, which represents a specific p-AKT phosphorylation site. 
In this study, we observed that the 56.9% and 55.2% of FMC samples expressed mTOR and p-mTOR 
respectively and we found a statistical association between mTOR and p-mTOR expression in the same 
samples (P <0.005) analysed. These data suggest that the mTOR protein is widely present in feline 
mammary carcinomas in its Ser2448 phosphorylated form, which is regulated by AKT [6]. These results are 
similar to human breast cancer, in which mTOR is expressed in 47% of cases [3] while p-mTOR expression has 
been reported in 24% to 69.7% of cases [14,40]. 
The correlation between mTOR and p-mTOR expression and prognosis, tumour histological grading, vascular 
invasion, tumour size and mitotic index did not demonstrated any statistically significant correlations, 
suggesting that neither mTOR nor its putative active form (p-mTOR) have a prognostic role in feline mammary 
carcinoma. In human breast cancer, the prognostic significance of p-mTOR expression is still controversial 
[3,14,41]. With regard to expression in TN-FMC, this study observed that mTOR and p-mTOR expression are 
statistically associated with the TN phenotype. This evidence is consistent with the results described in humans 
by Walsh and colleagues [3] that observed a higher expression of p-mTOR in TNBCs. As shown in Table 1 we 
investigated if the high expression of m-TOR and p-mTOR founded in our samples was correlated to HER2 
expression and we found that samples HER2 negatives are highly correlated to samples p-mTOR (P = 0.0005) 
and m-TOR (P = 0.0479) positives. These data confirm as in human [3] that p-mTOR is statistically correlated 
to triple negative phenotype. Interestingly, we found an opposite correlation between HER2 expression and 
mTOR phosphorylation. As during progression of cancers selection operates favouring cells with activated 
oncogenes, it is not surprising that cells showing the activation of a HER2 downstream signal, such as mTOR, 
do not require the simultaneous activation of the upstream signal, i.e. HER2. This for example also occurs in 
cells showing   either   RAS   or   RAF   mutations,   which   are 
mutually exclusive in colorectal cancer [42] and melanoma [43]. 
As described in results, western blot was performed mainly to identify the specify of antibodies and the cor-
responding proteins expression in feline mammary cells lines. The expression of PR, ER, HER2, mTOR, 
p-mTOR was confirmed by immunocytochemistry on each cellular monolayer (data not shown). On the 
basis of western blot analysis we can assess that 4/6 cell lines are negative for PR and ER, suggesting the non 
hormonal-dependent behavior of feline mammary carcinomas. Only FMCp cell line resulted ER and PR 
negative and with a low level of HER2 showing a triple negative behavior. All cell lines demonstrated 
high mTOR and p-mTOR expression with a higher expression of p-mTOR in the FMCp, FMCm and FNNm 
cell lines. The higher mTOR phosphorylation in the metastasis-derived cell line (FMCm) compared with its 
primary counterpart (FMCp) suggests a significant involvement of p-mTOR in metastasis, invasion and FMC 
tumor progression, such as in human breast cancer [14,44]. 
mTOR is considered a potential target for anti-tumor therapies [14,44] due to its role in breast cancer 
progression. The finding shown here, demonstrating the strong activation of mTOR in triple negative FMC, 
suggests that this tumor may be a suitable model to test innovative therapies against the human TNBCs. 
Conclusions 
Spontaneous tumours occurring in companion animals represent a significant resource for models to study 
innovative therapies for human cancer and feline mammary carcinoma is considered a suitable model for human 
hormone independent breast cancer. In this study, we demonstrate that there is also a FMC subset defined as TN 
FMC, which is characterised by a statistically significant association with m-TOR and p-mTOR expression as 
demonstrated in human breast cancer. 
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